Molenaar et al. demonstrated that the inactivation of CDK2 leads to synthetic lethality in MYCN-overexpressing neuroblastomas [134], thereby re-establishing CDK2 as a viable therapeutic target in MYC-dependent malignancies. Here, MYCN is linked to neuroblastoma.